Table 3.
Detection of individual high-risk HPV genotypes by CLART and LA in 125 women with ≥ CIN2
| High-risk genotype | Prevalence | Agreement | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CLART, N (%) | LA, N (%) | Relative prevalence CLART vs. LA (95% CI) | CLART+/LA+ | CLART+/LA- | CLART-/LA+ | CLART-/LA- | Total agreement (95% CI) | Positive agreement (95% CI) | |
| 16 | 55 (44%) | 57 (46%) | 0.96 (0.73-1.27) | 55 (44%) | 0 (0%) | 2 (2%) | 68 (54%) | 98% (94-100) | 96% (88-100) |
| 18 | 18 (14%) | 18 (14%) | 1.00 (0.55-1.83) | 18 (14%) | 0 (0%) | 0 (0%) | 107 (86%) | 100% (97-100) | 100% (81-100) |
| 31 | 30 (24%) | 30 (24%) | 1.00 (0.64-1.55) | 30 (24%) | 0 (0%) | 0 (0%) | 95 (76%) | 100% (97-100) | 100% (88-100) |
| 33 | 21 (17%) | 22 (18%) | 0.95 (0.55-1.64) | 21 (17%) | 0 (0%) | 1 (1%) | 103 (82%) | 99% (96-100) | 95% (77-100) |
| 35 | 7 (6%) | 6 (5%) | 1.17 (0.40-3.37) | 6 (5%) | 1 (1%) | 0 (0%) | 118 (94%) | 99% (96-100) | 86% (42-100) |
| 39 | 4 (3%) | 12 (10%) | 0.33 (0.11-1.01) | 4 (3%) | 0 (0%) | 8 (6%) | 113 (90%) | 94% (88-97) | 33% (10-65) |
| 45 | 6 (5%) | 17 (14%) | 0.35 (0.14-0.87) | 6 (5%) | 0 (0%) | 11 (9%) | 108 (86%) | 91% (85-96) | 35% (14-62) |
| 51 | 15 (12%) | 17 (14%) | 0.88 (0.46-1.69) | 15 (12%) | 0 (0%) | 2 (2%) | 108 (86%) | 98% (94-100) | 88% (64-99) |
| 52 | 17 (14%) | 15 (12%) | 1.13 (0.59-2.17) | 11 (9%) | 6 (5%) | 4 (3%) | 104 (83%) | 92% (86-96) | 52% (30-74) |
| 56 | 6 (5%) | 9 (7%) | 0.67 (0.24-1.82) | 5 (4%) | 1 (1%) | 4 (3%) | 115 (92%) | 96% (91-99) | 50% (19-81) |
| 58 | 19 (15%) | 10 (8%) | 1.90 (0.92-3.92) | 10 (8%) | 9 (7%) | 0 (0%) | 106 (85%) | 93% (87-97) | 53% (29-76) |
| 59 | 9 (7%) | 10 (8%) | 0.90 (0.38-2.14) | 8 (6%) | 1 (1%) | 2 (2%) | 114 (91%) | 98% (93-100) | 73% (39-94) |
| 68 | 7 (6%) | 3 (2%) | 2.33 (0.62-8.82) | 0 (0%) | 7 (6%) | 3 (2%) | 115 (92%) | 92% (86-96) | 0% (0-31) |